Post-treated prostate cancer: normal findings and signs of local relapse on multiparametric magnetic resonance imaging

Abdominal Imaging

Volumn 40, Issue 7, 2015, Pages 2814-2838

  Lopes Dias, João ^a,d,e   Lucas, Rita ^b   Magalhães Pina, João ^a,e   João, Raquel ^a,e   Costa, Nuno Vasco ^a,e   Leal, Cecília ^c,e   Bilhim, Tiago ^a,e   Campos Pinheiro, Luís ^a,e   Mateus Marques, Rui ^a,e  

^a HOSPITAL DE SÃO JOSÉ   (Portugal)

^b HOSPITAL DE SANTO ANTÓNIO DOS CAPUCHOS   (Portugal)

^c HOSPITAL DE SANTA MARTA   (Portugal)

^d Nova Medica School ^*  (Portugal)

^e NOVA MEDICAL SCHOOL   (Portugal)

Author keywords

Multiparametric resonance imaging; Prostate cancer; Recurrence

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANDROGEN DEPRIVATION THERAPY; BIOCHEMICAL RECURRENCE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CRYOSURGERY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADICAL RETROPUBIC PROSTATECTOMY; REVIEW; TRANSRECTAL ULTRASONOGRAPHY; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY; TUMOR RECURRENCE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CRYOSURGERY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY;

EID: 84942501550     PISSN: 09428925     EISSN: 14320509     Source Type: Journal    
DOI: 10.1007/s00261-015-0473-1     Document Type: Review

References (49)

1. Barentsz JO, Richenberg J, Clements R, et al. (2012) ESUR prostate MR guidelines 2012. Eur Radiol 22(4):746–757
2. Turkbey B, Albert PS, Kurdziel K, et al. (2009) Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol 192(6):1471–1480
3. Choi YJ, Kim JK, Kim N, et al. (2007) Functional MR imaging of prostate cancer. Radiographics 27(1):63–75
4. Kirkham APS, Haslam P, Keanie JY, et al. (2013) Prostate MRI: who, when, and how? Report from a UK consensus meeting. Clin Radiol 68(10):1016–1023
5. Heidenreich A, Bellmunt J, Bolla M, et al. (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59(1):61–71
6. Roach MR III, Hanks G, Thames H Jr, et al. (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4):965–974
7. Beresford MJ, Gillatt D, Benson RJ, et al. (2010) A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence statement of search strategies used and sources of information. Clin Oncol 22(1):46–55
8. Rouvière O, Vitry T, Lyonnet D (2010) Imaging of prostate cancer local recurrences: why and how? Eur Radiol 20:1254–1266
9. Boorjian SA, Thompson RH, Tollefson MK, et al. (2011) Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 59(6):893–899
10. Mottet N, Bellmunt J, Bolla M, et al. (2011) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59(4):572–583
11. Brogsitter C, Zöphel K, Kotzerke J (2013) 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients. Eur J Nucl Med Mol Imaging 40(Suppl):S18–S27
12. Lecouvet E, El J, Collette L, et al. (2012) Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99 m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62:68–75
13. Beer AJ, Eiber M, Souvatzoglou M, et al. (2011) Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol 12(2):181–191
14. Gomez P, Manoharan M, Kim SS, et al. (2004) Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int 94:299–302
15. Gutzeit A, Doert A, Froehlich JM, et al. (2010) Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. Skeletal Radiol 39:333–343
16. Fuccio C, Castellucci P, Schiavina R, et al. (2012) Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. Eur J Radiol 81:893–896
17. Luboldt W, Kufer R, Blumstein N, et al. (2008) Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases. Radiology 249(3):1017–1025
18. Eiber M, Holzapfel K, Ganter C, et al. (2011) Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI. J Magn Reson Imaging 33:1160–1170
19. Liauw SL, Pitroda SP, Eggener SE, et al. (2013) Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. Int J Radiat Oncol Biol Phys 85(2):378–384
20. Joniau S, Van den Bergh L, Lerut E, et al. (2013) Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol 63(3):450–458
21. Tewari A, Sooriakumaran P, Bloch D, et al. (2012) Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. Eur Urol 62(1):1–15
22. Park BH, Jeon HG, Jeong BC, et al. (2014) Influence of magnetic resonance imaging in the decision to preserve or resect neurovascular bundles at robotic assisted laparoscopic radical prostatectomy. J Urol 192(1):82–88
23. Briganti A, Joniau S, Gontero P, et al. (2012) Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur Urol 61:584–592
24. Joniau S, Hsu C-Y, Gontero P, et al. (2012) Radical prostatectomy in very high-risk localized prostate cancer: long-term outcomes and outcome predictors. Scand J Urol Nephrol 46(3):164–171
25. Roethke MC, Lichy MP, Kniess M, et al. (2013) Accuracy of preoperative endorectal MRI in predicting extracapsular extension and influence on neurovascular bundle sparing in radical prostatectomy. World J Urol 31(5):1111–1116
26. Panebianco V, Salciccia S, Cattarino S, et al. (2012) Use of multiparametric MR with neurovascular bundle evaluation to optimize the oncological and functional management of patients considered for nerve-sparing radical prostatectomy. J Sex Med 9:2157–2166
27. Pound CR, Partin AW, Eisenberger MA, et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281(17):1591–1597
28. Amling CL, Bergstralh EJ, Blute ML, et al. (2001) Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 165(April):1146–1151
29. Cirillo S, Petracchini M, Scotti L, et al. (2009) Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 19:761–769
30. Sciarra A, Panebianco V, Salciccia S, et al. (2008) Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 54:589–600
31. Sella T, Schwartz LH, Swindle PW, et al. (2004) Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231:379–385
32. Casciani E, Polettini E, Carmenini E, et al. (2008) Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. Acta Radiol 190(5):1187–1192
33. Nilsson S, Norlén BJ, Widmark A (2004) A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol (Madr) 43(4):316–381
34. Haider M, Chung P, Sweet J, et al. (2008) Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 70(2):425–430
35. Kim C, Park B, Lee H (2009) Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. J Magn Reson Imaging 29(2):391–397
36. Morgan V, Riches S, Giles S, et al. (2012) Diffusion-weighted MRI for locally recurrent prostate cancer after external beam radiotherapy. AJR Am J Roentgenol 198(3):596–602
37. Donati OF, Il Jung S, Vargas HA, et al. (2013) Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy? Radiology 268(2):440–450
38. Arumainayagam N, Kumaar S, Ahmed HU, et al. (2010) Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy. BJU Int 106:991–997
39. Akin O, Gultekin DH, Vargas HA, et al. (2011) Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Eur Radiol 21:1970–1978
40. Pucar D, Hricak H, Kuroiwa K, et al. (2005) Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy—initial experience. Radiology 236:545–553
41. Ash D, Flynn A, Battermann J, et al. (2000) ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 57:315–321
42. Han K, Belldegrun A (2004) Third-generation cryosurgery for primary and recurrent prostate cancer. BJU Int 93:14–18
43. Fahmy W, Bissada N (2003) Cryosurgery for prostate cancer. Arch Androl 49:397–407
44. Rees J, Patel B, Macdonagh R, et al. (2004) Cryosurgery for prostate cancer. BJU Int 93:710–714
45. Aus G (2006) Current status of HIFU and cryotherapy in prostate cancer—a review. Eur Urol 50(5):927–934
46. Parivar F, Hricak H, Shinohara K, et al. (1996) Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology 48(4):594–599
47. Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation therapy for prostate cancer. JAMA 294(2):238–244
48. Hussain M, Tangen C, Higano C, et al. (2006) absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24(24):3984–3990
49. Stewart A, Scher H, Chen M, et al. (2005) Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23(27):6556–6560